Alnylam Pharmaceuticals Inc at Canaccord Genuity Growth Conference Transcript
Hi, everyone. Welcome, and thanks for attending Canaccord Genuity's 43rd Annual Growth Conference. My name is [Johan Kim,] and I'm an associate on Whitney Ijem's generic medicine and rare disease team. We're very excited to have the team from Alnylam Pharmaceuticals here, and it's my great pleasure to introduce Mr. Jeff Poulton, who is the CFO. Alnylam is a global biopharmaceutical company leading the space for RNAi therapeutics and programs to address unmet needs in generic medicines, cardio-metabolic diseases, the CNS space and many others.
And so with that, I'll turn it over to the team for their presentation.
Thank you. Thanks for including us. And it's nice to be here today to give you an update on the Alnylam story. I will be making some forward-looking statements during my presentation today. So let's get started. So I think probably most of you are aware that Alnylam is the leader in RNAi therapeutics, which is a whole new class of medicines that we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
